ELISA法监测肝移植患者他克莫司全血浓度  

Monitoring whole blood concentration of tacrolimus in 1190 samples from liver transplant recipients by ELISA

作　　者：夏东亚[1] 郭涛[1] 蒋苓[1] 

机构地区：[1]沈阳军区总医院药剂科

出　　处：《中国临床药理学与治疗学》2006年第8期933-936,共4页Chinese Journal of Clinical Pharmacology and Therapeutics

摘　　要：目的：通过监测肝移植患者他克莫司全血浓度,观察并建立他克莫司在三联免疫抑制用药方案中的理想治疗窗,为临床合理应用提供参考.方法：用ELISA法测定他克莫司全血浓度,对138例患者的1190例次监测结果进行比较分析.结果：他克莫司全血浓度随移植后时间延长而逐渐下降.肝移植后1个月内、第2～3个月、第4～6个月和＞6个月时,用ELISA法监测他克莫司全血谷浓度的推荐治疗窗范围应分别为8～15、6～12、5～10、3～8 μg·L-1,较为适宜.结论：常规监测他克莫司全血浓度,参考推荐治疗窗范围调整给药方案,可获得满意的免疫抑制治疗效果.AIM： To monitor the concentration of tacrolimus in whole blood in liver transplant recipients and establish an optimal therapeutic window of tacrolimus, in order to provide information for rational usage in clinic. METHODS： The whole blood concentrations of tacrolimus were measured by ELISA. The levels of tacrolimus in 1190 samples from 138 liver transplant recipients were compared and studied. RESULTS： The whole blood concentration of tacrolimus is gradually decreased with time after operation. The optimal therapeutic window of tacroli-mus for liver transplant recipients was 8 - 15μg·L^-1 within 1 month after operation, 6 - 12μg·L^-1 from the 2nd to 3rd months, 5 - 10μg·L^-1 from the 4th to 6th months and 3 - 8μg·L^-1 after 6 months, respectively. CONCLUSION： It is necessary to routinely monitor blood concentration of tacrolimus. The satisfying therapeutic effects will be obtained if dosage regimens will be individualized according to optimal therapeutic window.

关 键 词：他克莫司 治疗药物监测 ELISA法 

分 类 号：R965.2[医药卫生—药理学]